| Gene name: | CCR2 |
| Aging type: | Accelerate |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | UCB-MSC |
| Experiment: | Western blot//Knockdown//SA-β-gal activity assay |
| Description: | The significance of CCR2 was further validated by the fact that CCR2 KD cells had decreased SA-β-gal activity and p53-p21 pathway activation. Furthermore, overexpression of CCR2 in early-phase UCB-MSCs remarkably increased cellular senescence, as indicated by induction of SA-β-gal activity , activation of the p53-p21 signaling cascade, and downregulation of BMI1 expression. |
| Target gene: | BMI1 |
| Official symbol(s): | BMI1 |
| R-AG-Target gene: | Downregulation |
| Subcategory: | Unclear |
| Target gene experiment: | Western blot//Knockdown//SA-β-gal activity assay |
| Target gene description: | The significance of CCR2 was further validated by the fact that CCR2 KD cells had decreased SA-β-gal activity and p53-p21 pathway activation. Furthermore, overexpression of CCR2 in early-phase UCB-MSCs remarkably increased cellular senescence, as indicated by induction of SA-β-gal activity, activation of the p53-p21 signaling cascade, and downregulation of BMI1 expression. |
| Regulatory pathway: | P53-P21 |
| R-AG-Pathway: | Activation |
| Official symbol(s): | TP53-CDKN1A |
| Pathway experiment: | Western blot//Knockdown//SA-β-gal activity assay |
| Pathway description: | The significance of CCR2 was further validated by the fact that CCR2 KD cells had decreased SA-β-gal activity and p53-p21 pathway activation . Furthermore, overexpression of CCR2 in early-phase UCB-MSCs remarkably increased cellular senescence, as indicated by induction of SA-β-gal activity, activation of the p53-p21 signaling cascade, and downregulation of BMI1 expression. |
Annotation:
Loading,please wait...